Trials / Completed
CompletedNCT02318394
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of MEDI0562 in adult subjects with selected advanced solid tumors
Detailed description
This is a first-time-in-human (FTiH) Phase 1, multicenter, open-label, dose-escalation, and dose-expansion study of MEDI0562 to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and preliminary anti-tumor activity in adult subjects with selected advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MEDI0562 | Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops. |
Timeline
- Start date
- 2015-03-02
- Primary completion
- 2018-01-09
- Completion
- 2018-01-09
- First posted
- 2014-12-17
- Last updated
- 2018-01-29
Locations
12 sites across 2 countries: United States, South Korea
Source: ClinicalTrials.gov record NCT02318394. Inclusion in this directory is not an endorsement.